MyMSTeam

Ocrevus (Ocrelizumab)
- Approval: Approved by the FDA to treat both relapsing and primary progressive forms of multiple sclerosis
- Mechanism: Biologic immunomodulator that reduces the number of CD20-positive B cells, which are involved in nerve cell attacks
- Administration: Intravenous infusion once every six months Show Full Answer

Ocrevus (Ocrelizumab)
- Approval: Approved by the FDA to treat both relapsing and primary progressive forms of multiple sclerosis.
- Mechanism: Biologic immunomodulator that reduces the number of CD20-positive B cells, which are involved in nerve cell attacks.
- Administration: Intravenous infusion once every six months after initial loading doses.
- Common Side Effects:
- Infusion reactions (headache, dizziness, fever, nausea, itching, rash, flushed skin, low blood pressure, fast heartbeat)
- Infections of the skin and respiratory tract
- Serious Side Effects:
- Severe infusion reactions
- Increased risk for some types of cancer

Mavenclad (Cladribine)
- Approval: Approved by the FDA to treat adults with relapsing forms of multiple sclerosis, including relapsing-remitting MS and active secondary progressive MS. Typically prescribed when other treatments are ineffective or poorly tolerated.
- Mechanism: Immunomodulator that reduces the number of B and T lymphocytes, which contribute to autoimmune attacks in MS.
- Administration: Oral tablets taken during two separate treatment courses each year, with each course lasting two weeks and about a month between courses.
- Common Side Effects:
- Headache
- Low white blood cell count
- Upper respiratory tract infection
- Serious Side Effects:
- Increased risk for low blood cell counts
- Serious infections
- Blood disorders
- Liver toxicity or injury
- Risk of developing graft-versus-host disease (GVHD) after receiving blood transfusions

For more details, you can visit the respective pages:
- [Ocrevus](https://www.mymsteam.com/treatments/ocrevus)
- [Mavenclad](https://www.mymsteam.com/treatments/mavenclad)

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Ocrevus (Ocrelizumab) for Multiple Sclerosis | MyMSTeam

Mavenclad (Cladribine) for Multiple Sclerosis | MyMSTeam